Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.
Seres’ programs comprise:
SER-109: This product has completed a Phase 1b/2 study with results showing a clinical benefit in patients with recurring Clostridium difficile infection (CDI). The drug is currently being evaluated in a Phase 2 study in recurring CDI.
The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations.
SER-287: This product is in a Phase 1b study for mild-to-moderate ulcerative colitis (UC).
In The NEWS
Collaborating with Memorial Sloan Kettering (MSK)
Seres entered into a strategic, multi-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK). The collaboration is intended to support the translation of novel discoveries from MSK laboratories into first-in-field microbiome therapeutics across multiple new cancer indications, where the microbiome may play a critical role.
The agreement meant to:
1. Improve the morbidity and mortality in Hematopoietic Stem Cell Transplantation (HSCT) for cancer treatment through preventing of Transplant-Related Infections and of Graft Versus Host Disease (GVHD); and;
2. Increase the efficacy and safety of checkpoint inhibitors used for immuno-oncology treatment.
Both areas will be targeted using rationally-designed consortia of microbiome bacteria, a technology which Seres has pioneered in other therapeutic areas.
Under a multi-year sponsored research agreement. Seres and MSK will work jointly to study patient samples from MSK clinical studies, generating microbiome metagenomic signatures as well as other clinical data that are expected to aid in the design of novel microbiome therapeutics in these targeted disease states. According to the agreements Seres will obtain a global license to MSK’s intellectual property related to the use of bacterial compositions in treating HSCT patients and related areas, further bolstering Seres’ broad existing composition of matter and method of use patent estate.
MSK scientists believe that the combined insights and capabilities could be strongly synergistic and could lead to clinically meaningful therapeutic applications for patients with various cancers and serious conditions related to their treatment.
MSK investigators, led by Marcel van den Brink, M.D., Ph.D., have published clinical studies demonstrating a relationship between the diversity and composition of the microbiome in Hematopoietic Stem Cell Transplantation (HSCT) patients and their increased risk of bacterial infections and GVHD, both of which contribute to all-cause mortality.
Seres is currently developing SER-155, a rationally-designed, preclinical stage therapeutic candidate comprised of in vitro cultured bacterial species that aims to improve morbidity and mortality outcomes in HSCT patients.
Improving Checkoint Inhibition Immunotherapy
Researchers from Seres and MSK will also work together in immuno-oncology to precisely discover how the microbiome could improve the efficacy and safety of immuno-oncology checkpoint inhibitors. This research builds upon a recent MSK publication which describes, for the first time, the important role of the microbiome in the development of immunological adverse events in patients, and related preclinical work showing that the microbiome can enhance the efficacy of checkpoint inhibitors.
“We are looking forward to collaborating with Seres, a global leader in the development of microbiome therapeutics, as we work together to advance our collective insights into meaningful clinical advances for patients. Based upon our research in cancer patients as well as animal models at MSK, we believe there is potential to improve patient outcomes by addressing the critical roles of the microbiome,” said Dr. van den Brink.”
Prohost Observations
Improvements of Immunotherapy is occurring everyday through different approaches. The improvement this time is coming through a collaboration between MSK – a first class cancer center and the biotech firm Seres Therapeutics (MCRB), both have great insight into the microbiome.
Checkpoint inhibitors immunotherapy is revolutionizing the treatment of cancer. You can use the Prohost Website research engine to learn more about this treatment and the drugs used and the firms behind them and biotech firms that developed the products used in combination with them
Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal
Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy
Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.
Seres’ programs comprise:
SER-109: This product has completed a Phase 1b/2 study with results showing a clinical benefit in patients with recurring Clostridium difficile infection (CDI). The drug is currently being evaluated in a Phase 2 study in recurring CDI.
The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations.
SER-287: This product is in a Phase 1b study for mild-to-moderate ulcerative colitis (UC).
In The NEWS
Collaborating with Memorial Sloan Kettering (MSK)
Seres entered into a strategic, multi-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK). The collaboration is intended to support the translation of novel discoveries from MSK laboratories into first-in-field microbiome therapeutics across multiple new cancer indications, where the microbiome may play a critical role.
The agreement meant to:
1. Improve the morbidity and mortality in Hematopoietic Stem Cell Transplantation (HSCT) for cancer treatment through preventing of Transplant-Related Infections and of Graft Versus Host Disease (GVHD); and;
2. Increase the efficacy and safety of checkpoint inhibitors used for immuno-oncology treatment.
Both areas will be targeted using rationally-designed consortia of microbiome bacteria, a technology which Seres has pioneered in other therapeutic areas.
Under a multi-year sponsored research agreement. Seres and MSK will work jointly to study patient samples from MSK clinical studies, generating microbiome metagenomic signatures as well as other clinical data that are expected to aid in the design of novel microbiome therapeutics in these targeted disease states. According to the agreements Seres will obtain a global license to MSK’s intellectual property related to the use of bacterial compositions in treating HSCT patients and related areas, further bolstering Seres’ broad existing composition of matter and method of use patent estate.
MSK scientists believe that the combined insights and capabilities could be strongly synergistic and could lead to clinically meaningful therapeutic applications for patients with various cancers and serious conditions related to their treatment.
MSK investigators, led by Marcel van den Brink, M.D., Ph.D., have published clinical studies demonstrating a relationship between the diversity and composition of the microbiome in Hematopoietic Stem Cell Transplantation (HSCT) patients and their increased risk of bacterial infections and GVHD, both of which contribute to all-cause mortality.
Seres is currently developing SER-155, a rationally-designed, preclinical stage therapeutic candidate comprised of in vitro cultured bacterial species that aims to improve morbidity and mortality outcomes in HSCT patients.
Improving Checkoint Inhibition Immunotherapy
Researchers from Seres and MSK will also work together in immuno-oncology to precisely discover how the microbiome could improve the efficacy and safety of immuno-oncology checkpoint inhibitors. This research builds upon a recent MSK publication which describes, for the first time, the important role of the microbiome in the development of immunological adverse events in patients, and related preclinical work showing that the microbiome can enhance the efficacy of checkpoint inhibitors.
“We are looking forward to collaborating with Seres, a global leader in the development of microbiome therapeutics, as we work together to advance our collective insights into meaningful clinical advances for patients. Based upon our research in cancer patients as well as animal models at MSK, we believe there is potential to improve patient outcomes by addressing the critical roles of the microbiome,” said Dr. van den Brink.”
Prohost Observations
Improvements of Immunotherapy is occurring everyday through different approaches. The improvement this time is coming through a collaboration between MSK – a first class cancer center and the biotech firm Seres Therapeutics (MCRB), both have great insight into the microbiome.
Checkpoint inhibitors immunotherapy is revolutionizing the treatment of cancer. You can use the Prohost Website research engine to learn more about this treatment and the drugs used and the firms behind them and biotech firms that developed the products used in combination with them
Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal
Other Articles